Case Report

**Integrated imaging of systemic Langerhans cell histiocytosis in an infant**

Valentina Cariello, MD, Patrizia Lombardo, MD, Luisa Castelli, MD, Carmela Brillantino, MD, Carmela De Fusco, MD, Antonio Rossi, Rocco Minelli, MD, Giuseppe Paviglianiti, MD, Roberto Grassi, MD, PhD, Eugenio Rossi, MD, PhD

**Department of Radiology, University of Campania “Luigi Vanvitelli”, Piazza Miraglia, Naples 80138, Italy**

**Department of Haematology, AORN “Santobono-Pausilipon”, Via Posillipo 226, Naples 80123, Italy**

**University “Campus Biomedico”, Via Álvaro del Portillo 21, Rome 00128, Italy**

**ARNAS “Civico - Di Cristina – Benfratelli”, Piazza Leotta Nicola 4, Palermo 90127, Italy**

**A R T I C L E   I N F O**

Article history:
Received 14 March 2022
Revised 30 April 2022
Accepted 5 May 2022
Available online 2 June 2022

Keywords:
Langerhans cells histiocytosis
Multisystem disease
Pediatric imaging
Hematological disorder

**A B S T R A C T**

Langerhans cell histiocytosis (LCH) is a myeloid neoplasm characterized by a clonal proliferation of CD1a+/CD207+ dendritic cells. Although individuals of any age can be affected, the disease is most common in infants younger than 5 years of age, especially males. A wide range of manifestations, from asymptomatic to aggressive, have been described, along with multisystem involvement. Even though the majority of bone lesions are observed, skin, lymph nodes, brain and lungs can also be involved. The involvement of hematopoietic system, including bone marrow, liver and spleen, is less frequent yet associated with worse prognosis, due to a worse treatment response. Diagnosis of LCH is based on the integration of clinical, laboratory, and radiological data; however, only histopathological examination might confirm it. As far as the spleen involvement is concerned, according to literature, it has been reported in about 15% patients with multisystem involvement, nonetheless only a few cases show parenchymal lesions. The present study reports the case of an infant with LCH with multisystem involvement, including bone, skin, liver, and spleen, with evidence of parenchymal lesions.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

---

* Competing Interests: The authors declare they have no competing financial interests or personal relationships that could appear to influence the work reported in this manuscript.
* Corresponding author.
  E-mail address: vivi.cariello@libero.it (V. Cariello).
  https://doi.org/10.1016/j.radcr.2022.05.016

1930-0433/© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Langerhans cell histiocytosis (LCH) is a rare hematological disorder previously known as “Histiocytosis X,” a nosological entity including Eosinophilic Granuloma, Lettere-Siwe disease, and Hand-Schuller-Christian disease, a spectrum of conditions characterized by an abnormal oligonal proliferation of myeloid-derived dendritic cells with similar features to epidermal Langerhans cells of the monocyte-macrophage system [1,2].

The hallmark of LCH is the accumulation of histiocytic cells, which typically show positivity for CD1a/CD207 (Langerin) on immune-histochemical examination, in any tissue or organ. This infiltration is followed by chronic inflammation along with the formation of granulomas [3].

For a long time, LCH has been considered as a reactive proliferation of Langerhans cells due to an inflammatory stress, as suggested by the benign histological appearance of the CD207+ cell, the associated inflammatory infiltrate and the characteristic local and systemic cytokine storm. However, the recent discovery of oncogenic BRAF recurring mutations in LCH, along with rare KRAS and TP53 mutations, supports the classification of this disease as a neoplasm [4].

Among more than 100 histiocytic disorders showing various clinical manifestations and histological patterns, LCH is the most common histiocytic disease with an annual incidence of approximately 2.9 per million per years.

Peak incidence is between 1 and 4 years of age, whereas a decreased incidence is observed thereafter [1,5-7]. Despite this, LCH may manifest at any age and has also been described in the elderly [8,9]. The disease occurs predominantly in males, with an M:F ratio of 3:2 [10,11]. Clinical presentation of LCH is widely variable, ranging from single indolent lesions to multisystem disease [4]. The most affected organs and systems are skin, bone, bone marrow, liver, spleen, lungs, lymph nodes and rarely the pancreas [12]. Bone is the most commonly involved site (80%), followed by skin (33%), whereas extrascousseous involvement (pituitary, liver, spleen, bone marrow, CNS) is less frequently seen [1,12,13]. Possible complications are musculoskeletal disabilities, hearing problems, skin scarring, neuropsychiatric defects and secondary malignancies like leukemia [14]. Diagnosis is challenging and is performed by a combination of clinical features, radiological findings and histopathological evidence of accumulation of histiocytic cells in tissues, aggregating in CD1a and CD207 expressing granulomas [1,15]. Age of onset, multisystem involvement and rate of disease progression represent the main prognostic factors [16,17]. Therapy is not always necessary, since the disorder is self-limiting in most children except for patients with multisystem involvement, for whom a treatment based on steroids and chemotherapeutic agents is required [16]. Here, we present the case of an infant with multisystemic LCH involving bone, skin, liver and spleen.

Case report

A 33-day-old male infant presented to the Pediatric Emergency Room with diffuse skin lesions and hepatosplenomegaly. The infant was born by normal spontaneous vaginal delivery following a full-term pregnancy. Birth weight was 3.7 kg. A skin rash involving the face was present at birth; however, it faded out within few days, as reported by his mother. In the following days, further skin lesions appeared over the whole body (Fig. 1).

For this reason, the infant was carried to the Pediatrician, who found the presence of the aforementioned skin lesions and hepatosplenomegaly. The infant was then taken to the ER, where all the necessary clinical-instrumental investigations were performed. On clinical examination, the infant presented with disseminated crusty skin lesions, similar to petechiae, which did not disappear on acupressure. Two other papular lesions were present on the scalp, the largest of which was about 2 cm. General conditions were fair, responsiveness and appetite were discrete. The urgently performed ultrasound of the abdomen confirmed the hepatosplenomegaly and showed the presence of multiple hypoechoic lesions in the hepatic and splenic parenchyma, the latter having the appearance of multiple images of point calcifications. Laboratory evaluation included complete blood count, serum electrolytes, liver enzymes, bilirubin, serum immunoglobulins and inflammatory makers, all of which were within normal limits, except for mild anemia and elevated CRP at 16.53 mg/dL (normal range: 0.5-1.0 mg/dL).

Considering the clinical-laboratory and instrumental findings, the infant was admitted to the Pediatric Ward for further investigations.

At admission, serological tests were performed to search for main perinatal (TORCH, VDRL, TPHA, EBV) and respiratory infections, with negative results, except for HSV IgG positivity.

A radiographic skeletal survey, a trans-fontanellar ultrasound and several clinical evaluations, including dermatological, neurological, cardiaciological, and hematological consultations, were also performed.

The skeletal radiograph showed 2 gross intraosseous osteolytic areas in the proximal epiphysis-metaphysis of the fibula, with interruption of the cortical bone, and in the proximal-middle diaphyseal part of the tibia (Fig. 2); a further...
The US examination of the abdomen performed at our Department substantially confirmed the findings of the previous ultrasound executed in the ER, ie, hepatosplenomegaly and multiple hypoechoic lesions of various sizes in both liver and spleen, the majority of which were featured by tiny internal echoes (Fig. 4).

On total body CT performed with contrast agent, liver and spleen appeared enlarged with an inhomogeneous parenchymal structure due to the presence of multiple hypodense nodular formations with hyperdense peripheral labrum (Fig. 5). Moreover, multiple osteolytic lesions of the pelvis were visible, on the iliac wings bilaterally, on the pubis and the left ischium in particular (Fig. 6). Additional bone injuries affected lumbar vertebral metamers, with micro lacunar aspect (Fig. 7), the proximal third of the clavicle and the body of the right scapula as well, with interruption of the bony cortex (Fig. 8).

The infant was therefore enrolled in the LCH-IV protocol, group 1 (patients with MS LCH), in order to receive a standard prednisone/vinblasticine regimen.

Discussion

Langerhans cell histiocytosis is an uncommon disease featured by Langerhans cells’ clonal proliferation and accumulation in various organs. The clinical presentation and the outcome of LCH depend on the patients’ age, the number of lesions and the degree of organ dysfunction at initial diagnosis.

The current classification system identifies 2 types of LCH referring to the number of involved sites [18,19]: single-system LCH (unifocal or multifocal) involving a single organ or system such as bone, skin, lymph nodes, lung and central nervous system, thymus or thyroid less frequently; multisystem LCH involving 2 or more organs or systems, instead [7,20].

Approximately 65%-70% of patients are affected by the single system disease [21,22], whereas the multisystem form is observed in 10% of LCH cases and has a poor prognosis, being often fatal. It is typically diagnosed in the first 2 years of life [23].

Furthermore, MS-LCH can be divided into a low-risk group and a high-risk group, evaluating risk organ involvement, ie, bone marrow, liver, and spleen [24,25]; lung is no longer considered as a risk organ [26,27]. The involvement of these sites leads to a worse treatment response and is consequently associated with worse prognosis.

LCH frequently emerge with a skin rash, as observed in our patient, often followed by other nonspecific symptoms such as fever, lack of appetite, weight loss, fatigue, irritability [28,29]. Signs of multiple organ failure have also been found, especially in the youngest children with MS disease [21], including, in order of decreasing frequency, skeleton (80%), skin (33%), pituitary (20%), liver, (15%), spleen (15%), bone marrow (15%), lung (12%), and central nervous system (CNS) without pituitary involvement (5%) [1,12].

Bone involvement is mostly unifocal and commonly appears as a painful tumor formation in a localized area [30]. Any bone may be involved, excluding hands and feet [7,24,31].

Fig. 2 – Bone radiograph shows 2 gross intraosseous osteolytic areas in the proximal epiphysis-metaphysis of the fibula, with interruption of the cortical bone, and in the proximal-middle diaphyseal part of the tibia (arrows).

Fig. 3 – Bone radiograph shows area of radiolucency in the context of the proximal metaphysis of the right femur (arrow). There is also visibility of the 2 osteolytic areas of fibula and tibia.

area of radiolucency was observed in the context of the proximal metaphysis of the right femur (Fig. 3).

Trans-fontanellar ultrasound did not show abnormalities in the brain parenchyma.

A skin biopsy of 2 lesions from the abdominal region and the left thigh respectively revealed diffuse proliferation of histoid cells (S100 +, CD1a +, Langerin +), and skin infiltration with histiocytes (CD68+). Genetic analysis also showed mutation of the BRAF gene.

This constellation of findings led to the diagnosis of multisystem Langerhans cell histiocytosis (LCH), therefore the infant was referred to our Department of Paediatric Haematology and Oncology.
However, flat bones seem to be favored, those of the skull in particular (orbit and mastoid), followed by mandible, ribs, pelvis, spine (including vertebral bodies, with frequent presence of a vertebra plana) [1,30,23,32], as well as the long bones, especially femur, as observed in our infant. At imaging, radiograph typically shows single or multiple osteolytic lesions, without marginal sclerosis or periosteal reaction [33].

Cutaneous involvement normally presents as erythematous papules or pustules, which can mimic a seborrheic dermatitis or eczema [7]. In children affected by neonatal form, as the case we report, disseminated brown to red papules with common central ulceration can be observed [1].

The hematopoietic system, including liver, spleen and bone marrow is commonly involved in very young children and represents a poor prognostic sign.

Hepatic involvement has been described in only 15% of LCH patients, although it is relatively frequent in the multisystem LCH (representing up to 60% of the cases) [3,34]. It often presents with hepatomegaly (liver > 3 cm below the costal margin in the midclavicular line), which may be accompanied by signs of organ dysfunction, as increased transaminases, hypoalbuminemia, jaundice and/or clotting factors deficiency [20,35]. Imaging findings can be various, due to the histopathological evolution of the process, consisting in 4 progressive

Fig. 4 – (a-e). Ultrasound imaging of the abdomen shows hepatomegaly with multiple hypoechoic parenchymal lesions (a-c) and splenomegaly with hypoechoic lesions and intralesional hyperechoic foci (d, e).
phases from an initial proliferative phase to a final fibrous phase [36]. In the early stages, hepatomegaly and parenchymal lesions are the most common findings, which are likely to be hypoechoic at US and hypoattenuating at CT; the fibrous phase, instead, typically shows a dysmorphic and nodular appearance of the liver parenchyma due to periportal fibrosis. Sclerosing cholangitis, which is progressive and may eventually require liver transplantation, is a possible evolution of the late stage due to biliary sclerosis [3,6,37].

Splenomegaly is not frequent, affecting about 15% of patients with LCH and it is mostly found in subjects with systemic disease. It may be either the consequence of parenchymal infiltration by Langerhans’ cells or might be secondary to portal hypertension as a result of periportal fibrosis. The most characteristic radiological finding of splenic affection is represented by splenomegaly (enlargement > 2 cm below the costal margin in the midclavicular line), typically followed by hypersplenism and subsequent cytopenia. In our patient, however, we could observe, along with splenomegaly, the presence of parenchymal lesions both on abdominal ultrasound and on CT scan. The literature only describes a few cases of splenic involvement with parenchymal lesions [38,37]. At CT, they become evident as hypodense nodules with ring enhancement, similar to those observed in liver. At US imaging, they appear as hypoechoic nodules [37]; nevertheless, a hypoechoic ultrasound appearance with multiple internal hyperechogenic foci, seen in our case, has not been described yet.

Treatment, at present, is only recommended for patients with extensive disease or symptomatic lesions. Asymptomatic patients and those with single-system disease usually require observation, as they are known to heal spontaneously. In case of unifocal lesions, curettage or surgical excision might be performed. Despite advances in understanding the pathogenetic mechanisms of LCH, treatment for disease with multi-system involvement is controversial. The current standard of frontline care for multifocal LCH remains systemic multiagent chemotherapy. The most common chemotherapeutic agents are vincristine, prednisone, etoposide and methotrexate, with a vincristine/prednisone association regimen employed as first-line therapy in this setting, to date [39]. In the present study, the patient was found to have a multiorgan form of the disease, thus he underwent a systemic treatment with prednisone/vinblastine. In case of severe and refractory LCH, patients may benefit from other therapies, including monoclonal

Fig. 5 – CT scans with contrast agent of the abdomen show multiple hypodense nodular formations with hyperdense peripheral labrum into liver and spleen.

Fig. 6 – CT scans (bone window) of the pelvis show multiple osteolytic lesions (arrows).
antibodies against CD1a, CD207, BRAF V600E inhibition and bone marrow transplantation [4,40–42].

**Patient consent**

Informed written consent was obtained from the parents of the infant for the publication of the case report and of all the related images.

**REFERENCES**

[1] Wang DS, Lu MY, Yang YL, Lin DT, Lin KH, Chang HH, et al. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience. J Formos Med Assoc 2021;120(1 Pt 3):594–601. doi:10.1016/j.jfma.2019.12.019.

[2] Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol 2013;8:1–20. doi:10.1146/annurev-pathol-020712-163959.

[3] Schmidt S, Eich G, Geoffray A, Hanquin S, Waibel P, Wolf R, et al. Extraosseous Langerhans cell histiocytosis in children. Radiographics 2008;28(3):707–26.

[4] Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med 2018;379(9):856–68. doi:10.1056/NEJMra1607548.

[5] Gargan ML, Wong JL, Leidhin CN, Owens C, Byrne A. Langerhans cell histiocytosis in children under 12 months of age: the spectrum of imaging and clinical findings: experience in an Irish tertiary referral centre. Eur J Radiol 2021;134:109375. doi:10.1016/j.ejrad.2020.109375.

[6] Pratap T, Jalal MJA, Rashmi R, Gopalakrishnabakhthan A, Vishnu Ak. Hepatobiliary and gastrointestinal involvement in Langerhans cell histiocytosis-spectrum of three cases. Indian J Radiol Imaging 2021;31(3):670–7. doi:10.1055/s-0041-1735505.

[7] Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol 2018;78(6):1025–44. doi:10.1016/j.jaad.2017.05.059.

[8] Imanaka A, Tarutani M, Itoh H, Kira M, Itami S. Langerhans cell histiocytosis involving the skin of an elderly woman: a satisfactory remission with oral prednisolone alone. J Dermatol 2004;31:1023–6.

[9] Stefanato CM, Andersen WK, Calonje E, Borghis S, Massone I, Kowalski JV, et al. Langerhans cell histiocytosis in the elderly: a report of three cases. J Am Acad Dermatol 1998;39(2 pt 2):375–8.

[10] Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer 2008;51:71–5.

[11] Yagi C, Varan A, Caglar M, Söylemezoğlu F, Sungur A, Orhan D, et al. Langerhans cell histiocytosis: retrospective analysis of 217 cases in a single center. Pediatr Hematol Oncol 2008;25:399–408.

[12] Staemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter JI. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 2008;51:76e81.

[13] Laurencikas E, Gavhed D, Staemark H, van’t Hooft J, Prayer D, Grois N, et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr Blood Cancer 2011;56:250e7.

[14] Musa J, Siddick AB, Ahmetgjekaj I, Rahman M, Guy A, Rahman A, et al. Multifocal Langerhans cell histiocytosis in a child. Radiol Case Rep 2021;16(9):2726–30. doi:10.1016/j.radcr.2021.06.052.

[15] Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013;60:175e84.

[16] Bi L, Sun B, Lu Z, Shi Z, Wang D, Zhu Z. Langerhans cell histiocytosis with multisystem involvement in an infant: a case report. Exp Ther Med 2015;9(6):2137–40. doi:10.3892/etm.2015.2396.
[17] Minkov M, Prosh H, Steiner M, Grois N, Pöttschger U, Kaatsch P, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005;45:802–7.

[18] Minkov M. Multisystem Langerhans cell histiocytosis in children. Current treatment and future directions. Pediatr Drugs 2011;13:75–86.

[19] Donadieu J, Chalard F, Jeziorski E. Medical management of Langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother 2012;13:1309–22.

[20] Jeziorska M, Stefanowicz J, Romanowicz G, Kosik W, Lange M. Langerhans cell histiocytosis in children—a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatol Alergol 2016;33(1):6–17. doi:10.5114/pdia.2017.67095.

[21] Morren MA, Broecke KV, Vangheeberegen L, Sillevis-Smit JH, Van Den Bergh P, Hauben E, et al. Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer 2016;63:486–92.

[22] Morimoto A, Ishida Y, Suzuki N, Ohga S, Shioda Y, Okimoto Y, et al. Nationwide survey of single-system single site Langerhans histiocytosis in Japan. Pediatr Blood Cancer 2010;54:98–102.

[23] Zaveri J, La Q, Yarmish G, Neuman J. More than just Langerhans cell histiocytosis: a radiologic review of histiocytic disorders. Radiographics 2014;34(7):2008–24.

[24] Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr 2008;20(1):23–9. doi:10.1097/MOP.0b013e3282f45ba46.

[25] Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol 2016;34(25):3023–30. doi:10.1200/JCO.2015.65.95087.

[26] Ronceray L, Potschger U, Janka G, Gadner H, Minkov M. German Society for Pediatric Hematology and Oncology, Langerhans Cell Histiocytosis Study Group. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr 2012;161:129–33.

[27] Braier J, Latella A, Balancini B, Castañe C, Rosso D, Chantada G, et al. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:765–9.

[28] Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances in Langerhans histiocytosis. Pediatr Int 2014;56:451–61.

[29] Zinn DJ, Chaokraborty R, Allen CE. Langerhans cell histiocytosis: emerging insights and clinical implications. Oncol J 2016;30:122–39.

[30] Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood 2020;135(15):1319–91. doi:10.1182/blood.2019000934.

[31] Hashimoto K, Nishimura S, Sakata N, Inoue M, Sawada A, Akagi M. Treatment outcomes of Langerhans cell histiocytosis: a retrospective study. Medicina (Kaunas) 2021;57(4):356. doi:10.3390/medicina57040356.

[32] Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK, et al. Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer 1995;76(12):2471–84.

[33] Stuill MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics 1992;12(4):801–23.

[34] Yi X, Han T, Zai H, Long X, Wang X, Li W. Liver involvement of Langerhans’ cell histiocytosis in children. Int J Clin Exp Med 2015;8(5):7098–106.

[35] Postini AM, Brach del Prever A, Pagano M, Rivetti E, Berger M, Asaftei SD, et al. Langerhans cell histiocytosis: 40 years’ experience. J Pediatr Hematol Oncol 2012;34:353–8.

[36] Engelbreth-Holm J, Teilum G, Christensen E. Eosinophil granuloma of Bone-Schüller-Christian’s disease. Acta Med Scand 1944;118:292–312.

[37] Mampaey S, Warner F, Van Hedent E, De Schepper AM. Imaging findings in Langerhans’ cell histiocytosis of the liver and the spleen in an adult. Eur Radiol 1999;9(1):96–8. doi:10.1007/s00330050636.

[38] Muwakkit S, Gharagozloo A, Souid AK, Spirt BA. The sonographic appearance of lesions of the spleen and pancreas in an infant with Langerhans’ cell histiocytosis. Pediatr Radiol 1994;24(3):222–3. doi:10.1007/BF02122000.

[39] Monsereensorn C, Rodriguez-Galindo C. Clinical characteristics and treatments of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 2015;29(5):853–73. doi:10.1016/j.hoc.2015.06.005.

[40] Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120:e28–e34.

[41] Haroche J, Cohen–Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495–1500.

[42] Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs 2011;13(2):75–86. doi:10.2165/113538540-00000000-00000.